PTA-23288-52541
2 vaccinations
1 coded response
11 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 223 / VA
- Registered
- 2021-11-08
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-09
Dose 1 — Janssen/Johnson & Johnson
-
2021-11-04
Dose 2 — Pfizer-BioNTech
-
2021-11-08
Registered in v-safe
- 2021-11-08
- 2021-11-09
- 2021-11-11
- 2021-11-18
- 2021-11-25
- 2021-12-02
- 2021-12-09
- 2021-12-16
- 2022-02-03
-
2022-05-05
Survey response — 6 months, dose 2MedDRA: Pre-eclampsia — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: PreeclampsiaMedDRA releases: 2024-11 · check-in free text available
-
2022-05-05
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prHospitalization · 1 call case(s)
-
2022-05-06
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2022-11-06
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-09 | Janssen/Johnson & Johnson | No |
| 2 | 2021-11-04 | Pfizer-BioNTech | No |
Call center
1 call center case
1 successful
Free text
Release 11 — 6 months, dose 2
Symptoms: Preeclampsia
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Pre-eclampsia | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release